

## **Prevalence and determinants of poor glycemc control among diabetic chronic kidney disease patients on maintenance hemodialysis in Tanzania**

Emmanuel Arthur Mfundo<sup>1,2</sup>, Alphonse Ignace Marealle<sup>2</sup>, Goodluck G. Nyondo<sup>3</sup>, Martine A. Manguzu<sup>2</sup>, Deus Buma<sup>4</sup>, Peter Kunambi<sup>5</sup>, Ritah F. Mutagonda<sup>2#</sup>

### **Authors' affiliations:**

<sup>1</sup>Quality Assurance Department, National Health Insurance Fund, NSSF-Kaloleni Plaza P.O Box 16110 Arusha.

<sup>2</sup>Department of Clinical Pharmacy and Pharmacology, Muhimbili University of Health and Allied Sciences, P.O Box 65013, Dar es Salaam.

<sup>3</sup>Department of Medicinal Chemistry, School of Pharmacy, Muhimbili University of Health and Allied Sciences, P.O Box 65013, Dar es Salaam, Tanzania.

<sup>4</sup>Department of Clinical Research, Training and Consultancy, Muhimbili National Hospital, P.O Box 65000 Dar es Salaam.

<sup>5</sup>Department of Clinical Pharmacology, Muhimbili University of Health and Allied Sciences, P.O Box 65001, Dar es Salaam.

**#Corresponding author:** Dr. Ritah F. Mutagonda

**Email:** ritah.mutagonda@muhas.ac.tz      Mobile number: +255 713 816 481

## ABSTRACT

**Background:** Poor glycemic control in diabetic chronic kidney disease (CKD) patients on maintenance hemodialysis is of great challenge, resulting in increased risk of morbidity and mortality. This study aimed to determine the prevalence and determinants of poor glycemic control among diabetic CKD patients on maintenance hemodialysis.

**Methodology:** A cross-sectional study was conducted in 12 dialysis centers located in four regions of Tanzania from March to June 2023. The study population was diabetic CKD patients above 18 years on maintenance hemodialysis for three months or more. A consecutive sampling technique was used for patient recruitment, and a semi-structured questionnaire was used to collect data. The primary outcome was poor glycemic control which was considered when glycated hemoglobin (HbA1c) levels were  $< 6\%$  or  $> 8\%$ . Statistical Package for Social Sciences (SPSS) version 23 was used for data analysis. Univariate and multivariable regression models were used to evaluate the determinants of poor glycemic control. A p-value  $< 0.05$  was considered statistically significant.

**Results:** Out of 233 enrolled patients, the overall prevalence of poor glycemic control was 55.4%, whereby 27.0% had HbA1c  $< 6\%$  and 28.33% had HbA1c  $> 8\%$ . A high risk of HbA1c  $> 8\%$  was observed among patients who were on antidiabetic medication (2.16 (95% CI: 1.06– 4.41)  $p = 0.035$ ) and those attending dialysis sessions less than 3 times a week (1.59 (95% CI: 1.02– 2.48)  $p = 0.04$ ). While the predictor of HbA1c  $< 6\%$  was the type of dialyzer used (0.57 (95% CI 0.36 – 0.87)  $p = 0.020$ ).

**Conclusion:** There is a high prevalence of poor glycemic control among diabetic CKD patients. Patients who were on antidiabetic medication and those who had less than three dialysis sessions had a high risk of HbA1c  $> 8\%$ . In contrast, those dialyzed using glucose-free dialysates had a high risk of HbA1c  $< 6\%$ .

**Keywords:** *Diabetes mellitus, Chronic Kidney Disease, Glycemic control, Hemodialysis, Antidiabetic medications, Glycated hemoglobin*

## 1 **Background**

2 Glycemic control in diabetic chronic kidney disease (CKD) patients is a great challenge due to  
3 altered glucose homeostasis, gluconeogenesis, tubular glucose reabsorption and inaccuracy of  
4 glycemic regulation metrics (1). Furthermore, changed renal pharmacokinetics of  
5 antihyperglycemic agents (AHA), uremic milieu, and dialysis therapy also contribute to this  
6 challenge (2). Based on the severe risk of hyperglycemia and hypoglycemia in patients with  
7 diabetic end-stage renal disease (ESRD), glycemic control is of paramount importance.

8 A study conducted in India showed a higher frequency of hypoglycemia in diabetic CKD patients  
9 compared to those without CKD. Moreover, a high mortality rate was associated with  
10 hypoglycemia among these patients (3). In addition, a significant association has been reported  
11 between poor glycemic control and low survival rates in diabetic CKD patients on hemodialysis  
12 compared to individuals with proper glycemic control. Notably, cardiovascular and infections were  
13 significant causes of death in this patient population (4). Furthermore, alteration in metabolism  
14 and elimination of antihyperglycemic agents (AHA) contribute to the incidence of hypoglycemia  
15 in diabetic hemodialysis patients (3,5).

16 A study conducted in Canada reported a 54% prevalence of poor glycemic control among diabetic  
17 patients undergoing hemodialysis (6). In addition, another study conducted in Tanzania reported  
18 glycemic control to be positively linked with adherence to antidiabetic medications, where  
19 optimum glycemic control was achieved in patients with good adherence to medication (7). In  
20 contrast, poor glycemic control is associated with non-adherence to antidiabetic medications,  
21 leading to hyperglycemia-related complications such as coronary artery disease (CAD),  
22 cardiovascular disease (CVD), hypertension, hyper dyslipidemia, poor patient quality of life, and  
23 prolonged hospital admissions, which increase healthcare costs (8).

24 Tanzania guideline on hemodialysis recommends all patients have baseline measurements of their  
25 blood sugar level and glycated hemoglobin (HbA1C) at the time of initiation of dialysis therapy.  
26 HbA1c between 7% and 8%, fasting blood sugar <7.7mmol/L and postprandial blood sugar  
27 11.1mmol/L are ideal targets, but epidemiological data recommends HbA1c from 6% to 8%, which  
28 is associated with decreased mortality rates (9).

29 Several factors determine the glycemic control of diabetic patients with or without renal failure,  
30 which includes eating a healthy diet, physical exercise, blood transfusion, elevated blood urea  
31 nitrogen (BUN), hemodialysis procedures, use of EPO, medication dose, and adherence (2,10).  
32 Accumulation of uremic toxins among diabetic CKD patients compromises the quality of life due  
33 to increased risk of uremia, development of insulin resistance, decreased hepatic insulin  
34 metabolism, uremic malnutrition, anaemia, gastritis, and increased risk of hospitalization due to  
35 cognitive impairment (11,12). Therefore, adequately removing uremic toxins and other waste  
36 products from the patient's blood through hemodialysis improves the quality of life and survival  
37 rate of this patient group.

38 Despite the importance of glycemic control to diabetic CKD patients on maintenance dialysis,  
39 there is limited data in sub-Saharan Africa, including Tanzania. Therefore, this study aimed to  
40 evaluate the prevalence and determinants of poor glycemic control among diabetic CKD patients  
41 attending hemodialysis centers in Tanzania.

## 42 **Methods**

### 43 **Study design and settings**

44 A cross-sectional study was conducted at selected hemodialysis centers in Tanzania from 1<sup>st</sup> March  
45 to 30<sup>th</sup> June 2023. The enrolling sites were Muhimbili National Hospital (MNH) Upanga and

46 Mloganzila centers, CCBRT Hospital, Hubert Kairuki Hospital, TMJ Hospital, Hindu Mandal  
47 Hospital and Hindu Mandal Polyclinic, in Dar es Salaam region, Benjamin Mkapu Hospital found  
48 in Dodoma, NSK Hospital, Mt. Meru Hospital and Moyo Medicare specialized polyclinic in  
49 Arusha region and Bugando Medical Centre in Mwanza region. These centers were selected  
50 because they serve most patients from all parts of Tanzania, and they were confirmed to monitor  
51 patients' glycemetic control using glycated hemoglobin assay. In addition, in all these centers,  
52 diabetic CKD patients are under the care of the nephrologists.

### 53 **Study population**

54 The study population consisted of diabetic CKD patients on maintenance hemodialysis at dialysis  
55 centers in Tanzania.

### 56 **Inclusion and exclusion criteria**

57 The study included diabetic hemodialysis patients aged  $\geq 18$  years on maintenance hemodialysis  
58 for  $\geq 3$  months. It excluded critically ill patients who failed to express and consent themselves,  
59 those who voluntarily refused to be included, and those who had no HbA1c results within three  
60 months.

### 61 **Sample size calculation**

62 A sample size of 380 participants was obtained using a prevalence of 54% of poor glycemetic control  
63 in diabetes patients on hemodialysis conducted in Canada with a confidence level of 95% and a  
64 margin of error of 5% (13).

### 65 **Sampling strategy**

66 Purposive sampling of regions and health facilities was used to enroll facilities providing dialysis  
67 services and having the laboratory capacity to monitor glycemetic control regularly. Then a  
68 consecutive sampling technique was used to enroll patients in the selected facilities.

## 69 **Data collection**

70 Primary data such as sociodemographic characteristics, duration of diabetes and dialysis services,  
71 weight, height, and diabetes-related complications were collected from patients using a semi-  
72 structured questionnaire. Secondary data such as the patients' medical history and type of  
73 investigations hemoglobin level (three months), glycosylated hemoglobin (one month), blood urea  
74 nitrogen (BUN) (three months), serum creatinine (one month), diabetic medications and other  
75 concomitant medications were collected from the patient's hospital records.

## 76 **Data analysis**

77 Data were analyzed using Statistical Package for Social Sciences (IBM-SPSS-version 23).  
78 Continuous variables were summarized using median and categorical variables were summarized  
79 using frequency and percentages. Variables were selected based on their potential association with  
80 glycemic control. Hemoglobin (Hb) levels were graded as either anemic or non-anemic based on  
81 Tanzania national dialysis guideline (Low Hb <10g/dl, Normal > 10g/dl). Average pre- and post-  
82 blood urea nitrogen (BUN) levels were used to compute urea reduction ratio (URR) as a maker for  
83 dialysis adequacy and a dialysis adequacy was regarded as urea reduction ratio (URR) of >65%.  
84 Furthermore, the Cockcroft and Gault equation was used to calculate estimated glomerular  
85 filtration (eGFR), and eGFR of <15ml/minutes was regarded as kidney failure stage five (14).  
86 Based on Tanzanian national dialysis guideline, HbA1c between 6% and 8% was considered  
87 adequate whereas HbA1c levels <6% and >8% were regarded as poor glycemic control. Prevalence  
88 ratios and their corresponding 95% confidence intervals (CI) were calculated by using univariate  
89 and multivariable regression models to show the determinants of poor glycemic control. Variables  
90 with  $p < 0.1$  on univariate analysis were considered for multivariate regression. P-value of  $< 0.05$   
91 was considered statistically significant.

92 **Results**

93 **Baseline socio-demographic characteristics of the study participants**

94 Among the study participants (n = 233), 70.4% were male, and the majority, 60.1%, were aged >  
95 60 years with a median age of 63 years, IQR (56, 68). About 46% of participants were retirees,  
96 and 96.6% had insurance, **Table 1**.

97 **Table 1: Baseline characteristics of the study participants (N = 233)**

<b>Variable</b>	<b>Frequency (n)</b>	<b>Percent (%)</b>
<b>Age group (years)</b>		
18 – 60	93	39.9
>60	140	60.1
Median age in years (IQR)	63 (56, 68)	
<b>Sex</b>		
Male	164	70.4
Female	69	29.6
<b>Marital status</b>		
Married	203	87.1
Not married	30	12.9
<b>Education Level</b>		
No formal to primary education	76	32.6
Secondary education	42	18.0
Vocational training/certificate	24	10.3
Diploma	38	16.3
Degree/Masters/PhD	53	22.7
<b>Occupation</b>		
Not employed	41	17.6
Formal employment	43	18.5
Business	39	16.7
Student	2	0.9
Retired	108	46.4
<b>History of cigarette smoking</b>		
Ever smoked	60	25.8
Never smoked	173	74.2
<b>History of alcohol use</b>		
Ever drunk	154	66.1
Never drunk	79	33.9
<b>Payment mode</b>		



98	Insurance	225	96.6
	Cash	8	3.4

99 **Clinical characteristics of the study participants**

100 The study participants were comprised of 96.1% with type 2 diabetes, 56.2% with a family history  
 101 of diabetes, 99.1% hypertensive, and 26.6% stopped antihyperglycemic agents due to the  
 102 resolution of their hyperglycemia for more than one year. The majority (93.6%) of participants  
 103 had CKD stage five, 88.4 were on dialysis three times per week, and 77.2% (n = 202) had attained  
 104 dialysis adequacy. In addition, 89.3% reported measuring blood glucose at home as a continuous  
 105 self-monitoring of diabetes, and 76% had developed diabetes-related complications such as  
 106 peripheral neuropathy (72.1%), retinopathy (34.3%), micro/macrovacular (9.4%) and  
 107 gastroparesis (3.4%). About 47.2% of patients had an arterio-venous fistula (AV-Fistula) as  
 108 vascular access, **Table 2**.

109 **Table 2: Clinical characteristics of the study participants (N = 233)**

Variable	Frequency (n)	Percent (%)
<b>Type of Diabetes</b>		
Type 1	9	3.9
Type 2	224	96.1
<b>Family history of diabetes</b>		
Yes	131	56.2
No	102	43.8
<b>History of hypertension</b>		
Yes	231	99.1
No	2	0.9
<b>Testing blood sugar at home</b>		
Yes	208	89.3
No	25	10.7
<b>Blood sugar readings (n = 208)</b>		
Usually high	9	4.3
Usually low	1	0.5
Within goals	97	46.6
Fluctuating between high and low	101	48.6

<b>Experience episode of hypoglycemia</b>		
Yes	125	53.6
No	108	46.4
<b>BMI (kg/m<sup>2</sup>)</b>		
Underweight (< 18.5)	13	5.6
Normal weight (18.5 – 24.9)	118	50.6
Over weight (25.0 – 29.9)	75	32.2
Obesity (≥ 30.0)	27	11.6
When do hypoglycemia occurs (n = 125)		
During dialysis	2	1.6
After dialysis	4	3.2
At Home	119	95.2
Diabetic induced complications		
Yes	177	76.0
No	56	24.0

110

111 **Prevalence of poor glycaemic control**

112 This study results revealed a prevalence of 55.4% of poor glycaemic control among diabetic CKD  
 113 patients on maintenance dialysis, which is constituted by 27.04% of participants with HbA1c <6%  
 114 and 28.33% with HbA1c > 8%).

115 **Determinants of glycaemic state in diabetic hemodialysis patients**

116 Patients who were still on antidiabetic medications had higher risk of poor glycaemic control  
 117 (HbA1c >8%) compared to those who stopped using medication due to resolution of  
 118 hyperglycemia 2.16 (95% CI 1.06 – 4.41) p = 0.035. Patients attending dialysis sessions once to  
 119 twice a week had a higher risk of poor glycaemic control (HbA1c >8%) than those attending thrice  
 120 a week 1.59 (95 CI 1.02 – 2.48), p = 0.040 (**Table 3**).

121 **Table 3: Univariable and multivariable analysis for predictors associated with high HbA1c**  
 122 **>8% levels among diabetic\_CKD patients on hemodialysis (n=170)**

Variable	Category	Univariable analysis		Multivariable analysis	
		cPR (95% CI)	P - value	aPR (95% CI)	P - value

<b>Mode of payment</b>	Insurance	0.6 (0.34 – 1.07)	<b>0.083</b>	0.93 (0.46– 1.88)	0.847
	Cash	1 <sup>a</sup>			
<b>DM medication status</b>	On medication	2.23 (1.06 – 4.69)	<b>0.034</b>	2.16(1.06 – 4.41)	<b>0.035</b>
	Not on medication	1 <sup>a</sup>			
<b>Insulin use</b>	Yes	1.27(0.86 – 1.87)	<b>0.226</b>	0.99 (0.66 – 1.49)	0.968
	No	1 <sup>a</sup>			
<b>Blood sugar reading at home</b>	Within goals	0.56 (0.35 – 0.90)	<b>0.017*</b>		
	Fluctuating	1 <sup>a</sup>			
<b>Episodes of hypoglycemia</b>	Yes	1.37 (0.92 – 2.06)	0.124	1.20 (0.81 – 1.79)	0.362
	No				
<b>URR (%)</b>	Inadequacy<65	1.34(0.86 – 2.07)	0.192*		
	Adequacy >=65	1 <sup>a</sup>			
<b>Dialysis frequency (per week)</b>	Once to twice	1.64 (1.09 – 2.45)	<b>0.016</b>	1.59(1.02 – 2.48)	<b>0.040</b>
	Thrice	1 <sup>a</sup>			
<b>Type of dialysate</b>	With glucose	0.61 (0.39 – 0.97)	<b>0.038</b>	0.71 (0.45 – 1.11)	0.136
	Glucose free	1 <sup>a</sup>			
<b>BT for past 3months</b>	Yes	1.76 (0.97 – 3.21)	0.063	1.55 (0.87 – 2.78)	0.139
	No	1 <sup>a</sup>			
<b>Vitamin D use</b>	Yes	0.67 (0.46 – 0.97)	<b>0.033</b>	0.72(0.49 – 1.06)	0.094
	No	1 <sup>a</sup>			
<b>Suffered infection</b>	Yes	1.51(0.95 – 2.39)	0.082	1.46 (0.92 – 2.33)	0.109
	No	1 <sup>a</sup>			

123

124 Patients dialyzed using glucose-containing dialysates had a lower risk of poor glycemic control  
 125 (HbA1c <6%) than those dialyzed with glucose-free dialysate 0.57 (95 CI 0.35 – 0.92), p = 0.020,  
 126 and **Table 4**.

127 **Table 4: Univariable and multivariable analysis for predictors associated with low HbA1c**  
 128 **<6% among diabetic-CKD patients on hemodialysis (n=167)**

Variable	Category	Univariable analysis		Multivariable analysis	
		cPR (95% CI)	P - value	aPR (95% CI)	P - value
<b>Marital status</b>	Not married	0.47 (0.19 – 1.16)	0.103	0.61(0.27 – 1.36)	0.228
	Married	1 <sup>a</sup>			

<b>DM medication status</b>	On medication	0.52 (0.36 – 0.76)	<b>0.001</b>	0.69 (0.37 – 1.29)	0.245
	Not on medication	1 <sup>a</sup>			
<b>Insulin use</b>	Yes	0.69 (0.39 – 1.21)	0.193	0.78 (0.39 – 1.53)	0.472
	No	1 <sup>a</sup>			
<b>Episodes of hypoglycemia</b>	Yes	0.78 (0.52 – 1.16)	0.213	0.88 (0.58 – 1.33)	0.547
	No				
<b>Type of dialysate</b>	With glucose	0.56 (0.36 – 0.87)	<b>0.010</b>	0.57 (0.35 – 0.92)	<b>0.020</b>
	Glucose free	1 <sup>a</sup>			
<b>Sulfonylurea use</b>	Yes	0.61 (0.38 – 0.97)	0.038	0.79 (0.42 – 1.49)	0.473
	No	1 <sup>a</sup>			
<b>BT for past 3months</b>	Yes	1.62 (0.77 – 3.4 1)	0.203	1.99 (0.98 – 4.05)	0.059
	No	1 <sup>a</sup>			
<b>Duration on dialysis (Months)</b>	<6.0	0.90 (0.32 – 2.54)	<b>0.840</b>	1.04(0.32 – 3.35)	0.953
	6.0 – 11.0	0.67(0.39 – 1.56)	<b>0.149</b>	074 (0.44 – 1.24)	0.254
	12.0 – 35.0	0.54 (0.32– 0.91)	<b>0.019</b>	0.61 (0.36 – 1.01)	0.056
	36.0 – 59.0	0.66 (0.39 – 1.09)	<b>0.108</b>	0.65 (0.40 – 1.07)	0.088
	>= 60.0	1 <sup>a</sup>			
<b>Calcium channel blocker use</b>	Yes	0.72 (0.45– 1.15)	0.167	0.62 (0.36 – 1.05)	0.074

129

## 130 Discussion

131 Our study aimed to determine the prevalence and determinants of poor glycemic control among  
 132 diabetic CKD patients on maintenance hemodialysis. Significant findings of this study include a  
 133 high prevalence (55.4%) of poor glycemic control among diabetic CKD patients in the population.  
 134 It was observed that being on medication and attending dialysis sessions only once to twice a week  
 135 were significantly associated with HbA1c >8% levels, while those who were dialyzed using  
 136 glucose-containing dialysates were significantly associated with HbA1c <6% levels.

137 The high prevalence of poor glycemic control in this study is in line with the findings from a study  
 138 conducted in Canada, which reported a prevalence of 54% among patients who developed diabetic-  
 139 related complications (13). Inadequate glycemic control with HbA1c >8% can contribute to the

140 development of diabetic-related complications such as diabetic neuropathy, retinopathy, and  
141 macro and microvascular complications. This was also evident in our study, whereby 76% of  
142 patients had diabetic-induced complications such as diabetic neuropathy, retinopathy and  
143 macro/microvascular complications (13). The HbA1c <6% level is known to contribute to  
144 increased mortality among diabetic CKD patients on maintenance hemodialysis. Two studies  
145 conducted in London, United Kingdom, investigated the association between HbA1c and mortality  
146 rate and showed a J-shaped distribution of mortality risks. The studies concluded that both  
147 deficient and high levels of HbA1c were related to increased mortality risks due to diabetic  
148 complications and hypoglycemia, respectively (15,16). Further studies need to be conducted in  
149 resource-constrained countries to investigate the risk of mortality in this group of patients.

150 This study showed that patients who were still on antidiabetic medication had a significantly higher  
151 risk of having HbA1c >8% levels compared to those who had their medications stopped due to the  
152 resolution of hyperglycemia. This might be due to insulin resistance associated with hyperuricemia  
153 in this patients' group and non-adherence to medication. Our study revealed that 33.9% of patients  
154 were non-adherent to medication, with about 55.2% of these having poor glycemic control. Our  
155 study findings correlate with the study conducted in Canada in which more patients who were on  
156 medication had poor glycemic control (13).

157 For the case of HbA1c <6%, our study showed that patients who were dialyzed using glucose-  
158 containing dialysate had a lower risk of developing inadequate low glycemic control compared to  
159 those patients dialyzed without glucose-containing dialysate. This is because some of the blood  
160 glucose is lost during dialysis procedures due to hemofiltration (17). Our study findings correlate  
161 with the study conducted in India, which reported higher hypoglycemic episodes in patients  
162 dialyzed with glucose-free dialysates when compared with glucose-containing dialysate (18).

163 Despite some potential benefits of using glucose-free dialysates, such as reducing risks of bacterial  
164 infection, reducing skin autofluorescence (SAF), which is a marker of glycation end products  
165 (AGEs), mobilizing lipid to maintain normal blood glucose (19), in order to avoid the risk of  
166 hypoglycemic episodes and extremely low glucose levels, glucose-containing dialysates are  
167 recommended.

168 Moreover, the study showed that patients having once to twice hemodialysis sessions per week  
169 had a higher risk of HbA1c >8% compared to those with three sessions per week. Dialysis  
170 frequency may be influenced by several factors but mainly the ability to pay for dialysis sessions.  
171 Tanzania has more than 60 million people, but only 4.8 million people are covered with insurance  
172 (20). Though during the study period, 96.6% of patients were covered with insurance, previous  
173 studies conducted in Tanzania have reported that the frequency of maintenance hemodialysis is  
174 significantly influenced by the mode of payment, whereby patients covered by health insurance  
175 had higher adherence to dialysis sessions compared to non-insured patients (21,22) More studies  
176 can be conducted to provide evidence on factors influencing dialysis frequency among insured  
177 patients.

178 In this study, there were some limitations, including the reluctance of the participants to provide  
179 the required information and economic constraints among the study participants, making some of  
180 them fail to pay for the prescribed three-per-week hemodialysis sessions and HbA1c assay. The  
181 effective use of available resources, including hospital records and providing adequate information  
182 during the consenting process, was used to mitigate the limitations.

### 183 **Conclusions**

184 This study indicates that the prevalence of poor glycemetic control in Tanzania is high among  
185 diabetic CKD patients on maintenance hemodialysis. Patients who had less than three dialysis

186 sessions per week had HbA1c >8%. We recommend tailored interventions to ensure that diabetic  
187 CKD receive three dialysis sessions per week. Moreover, patients who were dialyzed using  
188 glucose-free dialysates had poor low glycemic control, which emphasizes the significance of using  
189 glucose-containing dialysates in our settings.

#### 190 **Competing Interest**

191 The authors declare that there is no competing interest.

#### 192 **Funding**

193 This was a self-funded study.

#### 194 **Authors' contribution**

195 Authors contribution were as follows; EAM: Formulation of research idea, designed the research,  
196 data collection, data analysis, interpretation of the results, manuscript writing, AM: Approved the  
197 research idea and research design, interpretation of the results, review of the manuscript, final  
198 approval of the manuscript, RM: Approved the research idea and research design, interpretation  
199 of the results, review of the manuscript, final approval of the manuscript, DB: Approved the  
200 research idea and research design, review of the manuscript, final approval of the manuscript. PK:  
201 Data analysis, final approval of the manuscript.

#### 202 **Acknowledgement**

203 The authors acknowledge the management of National Health Insurance Fund (NHIF), staff and  
204 management of the data collection sites, Mr. Victor Njau, Mr. Devis Mhagama and staff of the  
205 Department of Clinical Pharmacy and Pharmacology, MUHAS.

#### 206 **Declaration**

207 **Ethics approval and consent to participate**

208 This study obtained ethical clearance from Muhimbili University of Health and Allied Sciences  
209 (MUHAS) institutional review board (Certificate number: MUHA-REC-02-2023-1533). In  
210 addition, permission to conduct this study in the selected facilities was sought from each hospital  
211 management. Written informed consent was obtained from each participant.

212 **Consent for publication**

213 Not applicable.

214 **References**

- 215 1. Hassanein M, Shafi T. Assessment of glycemia in chronic kidney disease. Vol. 20, BMC  
216 Medicine. BioMed Central Ltd; 2022.
- 217 2. Rhee CM, Leung AM, Kovesdy CP, Lynch KE, Brent GA, Kalantar-Zadeh K. Updates on  
218 the management of diabetes in dialysis patients. *Semin Dial*. 2014;27(2):135–45.
- 219 3. Archives of Clinical Nephrology Management of type 2 Diabetes in patients with Chronic  
220 Kidney Disease. 2017; 3:47–52.
- 221 4. Oomichi T, Emoto M, Tabata T, Morioka T, Tsujimoto Y, Tahara H, et al. Impact of  
222 glycemic control on survival of diabetic patients on chronic regular hemodialysis: A 7-year  
223 observational study. *Diabetes Care*. 2006;29(7):1496–500.
- 224 5. Neumiller JJ, Alicic RZ, Tuttle KR. Therapeutic considerations for antihyperglycemic  
225 agents in diabetic kidney disease. *Journal of the American Society of Nephrology*.  
226 2017;28(8):2263–74.



- 227 6. Harris SB, Ekoé JM, Zdanowicz Y, Webster-Bogaert S. Glycemic control and morbidity in  
228 the Canadian primary care setting (results of the diabetes in Canada evaluation study).  
229 Diabetes Res Clin Pract. 2005;70(1):90–7.
- 230 7. Kamuhabwa AR, Charles E. Predictors of poor glycemic control in type 2 diabetic patients  
231 attending public hospitals in Dar es Salaam. Drug Healthc Patient Saf. 2014 Oct 24;6:155–  
232 65.
- 233 8. Rwegerera GM. Adherence to anti-diabetic drugs among patients with Type 2 diabetes  
234 mellitus at Muhimbili National Hospital, Dar es Salaam, Tanzania- A cross-sectional study.  
235 2014; 8688:1–9.
- 236 9. Tanzania National guidelines for dialysis services in Tanzania. 2019;1–54.
- 237 10. Nakamura Y. Diabetes therapies in hemodialysis patients: Dipeptidase-4 inhibitors. World  
238 J Diabetes. 2015;6(6):840.
- 239 11. Somji SS, Ruggajo P, Moledina S. Adequacy of Hemodialysis and Its Associated Factors  
240 among Patients Undergoing Chronic Hemodialysis in Dar es Salaam, Tanzania. Int J  
241 Nephrol. 2020;2020.
- 242 12. Frankel A, Karalliede J, Montero RM, Pokrajac A, Winocour P, Fogarty D, et al. Clinical  
243 practice guidelines for management of hyperglycaemia in adults with diabetic kidney  
244 disease Writing group members Debasish Banerjee MD FRCP Indranil Dasgupta DM  
245 FRCP Correspondence Citation for this document. 2021.
- 246 13. Tascona DJ, Morton AR, Toffelmire EB, Holland DC, Iliescu EA. Adequacy of glycemic  
247 control in hemodialysis patients with diabetes. Diabetes Care. 2006;29(10):2247–51.

- 248 14. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney  
249 Disease. *Kidney Int.* 2020 Oct 1;98(4): S1–115.
- 250 15. Forbes A, Murrells T, Mulnier H, Sinclair AJ. Mean HbA<sub>1c</sub>, HbA<sub>1c</sub> variability, and  
251 mortality in people with diabetes aged 70 years and older: a retrospective cohort study.  
252 *Lancet Diabetes Endocrinol.* 2018 Jun 1;6(6):476–86.
- 253 16. Critchley JA, Carey IM, Harris T, DeWilde S, Cook DG. Variability in glycated hemoglobin  
254 and risk of poor outcomes among people with type2diabetesinalargeprimary care cohort  
255 study. *Diabetes Care.* 2019 Dec 1;42(12):2237–46.
- 256 17. Burmeister JE, Campos JF, Miltersteiner D da R. Efeito de diferentes níveis de glicose no  
257 dialisato sobre o risco de hipoglicemia durante hemodiálise em pacientes diabéticos [Effect  
258 of different levels of glucose in the dialysate on the risk of hypoglycaemia during  
259 hemodialysis in diabetic patients]. *J Bras Nefrol.* 2012;34(4):323–7.
- 260 18. Padmanabhan A, Velayudham B, Vijaykumar N, Allauddin S. Evaluation of glycemic status  
261 during the days of hemodialysis using dialysis solutions with and without glucose. *Saudi J*  
262 *Kidney Dis Transpl.* 2018;29(5):1021–7.
- 263 19. Li M, Li Y, Lv J, Xu H, Wu X, Wen W, et al. The effects of glucose-free and glucose-  
264 containing dialysate during dialysis in MHD patients: a prospective cross-over study.  
265 *Perfusion (United Kingdom).* 2023 Jan 1;38(1):178–85.
- 266 20. NHIF-Annual Report 2021/22.

267 21. Mohamedi S, Mosha IH. Hemodialysis Therapy Adherence and Contributing Factors  
268 among End-Stage Renal Disease Patients at Muhimbili National Hospital, Dar es Salaam,  
269 Tanzania. *Kidney and Dialysis*. 2022 Mar 21;2(1):123–30.

270 22. Meremo AJ, Ngilangwa DP, Mwashambwa MY, Masalu MB, Kapinga J, Tagalile R, et al.  
271 Challenges and outcomes of haemodialysis among patients presenting with kidney diseases  
272 in Dodoma, Tanzania. *BMC Nephrol*. 2017 Jul 4;18(1).

273

274